Clinical Trials Browser

Phase 2 × Recruiting × Pluvicto × Clear all

NCT06632977 2026-04-07

PREDICT

Phase 2 Recruiting

Prostatic Neoplasms

NCT06526299 2026-03-24

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Phase 2 Recruiting

Prostatic Neoplasms

NCT06288113 2026-03-13

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Phase 2 Recruiting

Prostatic Neoplasms

NCT06216249 2026-03-10

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Phase 2 Recruiting

Prostatic Neoplasms

NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Phase 2 Recruiting

Renal Insufficiency

NCT06145633 2026-01-28

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06866938 2026-01-06

ReaLuP

Phase 2 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06084338 2025-12-31

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Phase 2 Recruiting

Prostatic Neoplasms

NCT05766371 2025-12-30

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06200103 2025-09-11

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06738303 2025-08-27

CATCH-177

Phase 2 Recruiting

Prostatic Neoplasms

NCT06972628 2025-05-15

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Phase 2 Recruiting

Prostatic Neoplasms

NCT06449781 2025-02-10

PSMA-ADJUVO

Phase 2 Recruiting

Prostatic Neoplasms